PE Tech Report


Like this article?

Sign up to our free newsletter

Sherpa Healthcare Partners closes oversubscribed Fund II

Sherpa Healthcare Partners has held the closing of its oversubscribed Sherpa Healthcare Fund II. 

The fund focuses on early- to growth-stage investments in China healthcare sector to cover companies in biotech/biopharma, medical devices/diagnostics, and medical services. The Fund’s LPs include public pension plans, sovereign wealth funds, foundations, family offices, funds of funds, asset management companies, and other institutional investors.

Outstanding portfolio companies of Sherpa Healthcare Funds include Cytek Biosciences, New Horizon Health, Singleron, Epimab, NanoVision, Belief Biomed, Stroke Care, Blissbio, VisionX, Visen, and many more.

Kirkland & Ellis advised Sherpa Healthcare Partners.

Like this article? Sign up to our free newsletter




Blackstone Private Equity